DNLI vs SPRB
DNLI: Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the blood-brain barrier for the treatment of neurodegenerative diseases and rare disorders. SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B.
Side-by-side fundamentals
| Metric | DNLI | SPRB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $23.64 | $44.60 | |
| Market cap as of 2026-07-23 | $3.7B | $123M | |
| PEG as of 2026-07-23 | -1.05 | n/a | |
| Net margin as of 2026-07-23 | -36.5% | -1079.9% | DNLI higher |
| Operating margin as of 2026-07-23 | -49.7% | -1143.4% | DNLI higher |
| ROE as of 2026-07-23 | -50.1% | -155.4% | DNLI higher |
| ROA as of 2026-07-23 | -44.2% | -101.7% | DNLI higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.19 | DNLI lower |
| Beta as of 2026-07-23 | 0.99 | 3.45 | |
| 1-year return as of 2026-07-22 close | +72.3% | +423.9% | SPRB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.